• Reuters

  • SHARE

As the U.S. Food and Drug Administration considers whether to approve the innovative Iqos smoking device, made by Philip Morris International Inc., researchers have raised concerns about studies submitted to the authority, half of which were conducted in Japan.

With a decision expected this year, former employees and contractors have described a number of irregularities involving clinical trials that underpin the tobacco giant’s application to the agency.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.

SUBSCRIBE NOW

PHOTO GALLERY (CLICK TO ENLARGE)